Anti-CD19 CAR-T cell therapy exerts selective pressure on CD19-expressing B-ALL, leading to tumor growth with different lineage markers and the loss of the CD19 target antigen (53, 60). The gene discussed is CD19; the disease is acute lymphoblastic leukemia.